# Cytos Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytos-biotechnology

- Industry: Biotechnology
- Headquarters: Schlieren, Switzerland
- Website: www.cytos.com
- Total disclosed funding: $65M
- Latest round: Series C (Jan 23, 2002)
- Investors on record: 15

## About

Cytos Biotechnology Ltd. is engaged in the development of innovative biopharmaceuticals, focusing on therapeutic solutions for autoimmune diseases and allergies, leveraging proprietary technologies to create effective treatments.Founded in 1995 and headquartered in Schlieren, Switzerland, Cytos Biotechnology Ltd. specializes in the research and development of biopharmaceuticals. The company has undergone changes in its business strategies over the years, but specific pivots are not documented. Cytos Biotechnology has successfully executed 9 deals in its operational history, with its most recent deal occurring on October 29, 2002, when the company was listed on the Swiss Exchange. The latest funding round, a PIPE, raised CHF 3.200 mn, bringing the total amount raised by the company to CHF 3.200 mn.Cytos Biotechnology focuses on the development of biopharmaceutical products designed to treat autoimmune diseases and allergies. The company utilizes proprietary technologies to create innovative therapies intended to improve patient outcomes in these areas. Details regarding specific product offerings are not provided.Cytos Biotechnology generates its revenue through the commercialization of its biopharmaceutical products, targeting healthcare providers and institutions. The revenue is derived from product sales that have received necessary regulatory approvals for use in treating specific medical conditions. The company collaborates with various partners to enhance the distribution and accessibility of its therapies in the market.Cytos Biotechnology is focused on advancing its product pipeline to introduce new therapies targeting autoimmune diseases and allergies. Plans for market expansion are not detailed, nor is specific release date information for upcoming products available. The funding raised during the recent PIPE will be utilized to support ongoing research and development efforts, as well as to enhance operational capabilities, although further specifics on the deployment of these funds are not outlined.

## Funding rounds

- Series C, Jan 23, 2002, $27M — HBM Partners, Andera Partners, Julius Bär, Zurich Cantonal Bank, Adamant Biomedical Investments AG, Equity4Life
- Series B, Jul 25, 2000, $31M — Alta Partners, Vontobel Asset Management (Private Wealth), HealthCap, Global Life Science Ventures, Novartis Venture Fund, Aventic Partners, Lombard Odier Asset Management, Credit Suisse Innoventure Capital AG, NMT Management AG
- Series A, Jun 1, 1999, $7.1M — Global Life Science Ventures, Novartis Venture Fund, Credit Suisse Innoventure Capital AG

## Investors

- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Credit Suisse Innoventure Capital AG (https://capitalatlas.ai/funds/credit-suisse-innoventure-capital-ag) — Series A, Series B
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B
- Vontobel Asset Management (Private Wealth) (https://capitalatlas.ai/funds/vontobel-asset-management-private-wealth) — Series B
- HealthCap — Series B
- Aventic Partners (https://capitalatlas.ai/funds/aventic-partners) — Series B
- Lombard Odier Asset Management — Series B
- NMT Management AG — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series C
- Julius Bär — Series C
- Zurich Cantonal Bank — Series C
- Adamant Biomedical Investments AG — Series C
- Equity4Life (https://capitalatlas.ai/funds/equity4life) — Series C